Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Axcella Health (AXLA – Research Report), Alnylam Pharma (ALNY – Research Report) and Cytokinetics (CYTK – Research Report).
Axcella Health (AXLA)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Axcella Health today and set a price target of $10.00. The company’s shares closed last Friday at $1.71, close to its 52-week low of $1.35.
According to TipRanks.com, Arce is a 4-star analyst with an average return of
Axcella Health has an analyst consensus of Strong Buy, with a price target consensus of $8.50, a 391.3% upside from current levels. In a report issued on September 30, Wedbush also reiterated a Buy rating on the stock with a $9.00 price target.
Alnylam Pharma (ALNY)
Berenberg Bank analyst Zhiqiang Shu maintained a Hold rating on Alnylam Pharma today and set a price target of $184.00. The company’s shares closed last Friday at $200.16.
According to TipRanks.com, Shu ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alnylam Pharma with a $235.95 average price target.
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Cytokinetics, with a price target of $75.00. The company’s shares closed last Friday at $48.45.
According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Cytokinetics is a Strong Buy with an average price target of $68.11, representing a 40.0% upside. In a report issued on September 23, Mizuho Securities also maintained a Buy rating on the stock with a $80.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AXLA:
- H.C. Wainwright Keeps Their Buy Rating on Ocular Therapeutix (OCUL)
- H.C. Wainwright Keeps Their Buy Rating on TRACON Pharmaceuticals (TCON)
- H.C. Wainwright Sticks to Their Buy Rating for scPharmaceuticals (SCPH)
- Astria Therapeutics (ATXS) Receives a Buy from H.C. Wainwright
- H.C. Wainwright Keeps Their Buy Rating on Scholar Rock Holding (SRRK)